Table 1.
Baseline table of all patients with a single primary cutaneous melanoma in the Netherlands from 2000 to 2014a
| Characteristic | Total (n = 48 361) | SSM (n = 38 373) | NM (n = 7059) | LMM (n = 2500) | ALM (n = 429) |
|---|---|---|---|---|---|
| Subtype, No. (%) | |||||
| SSM | 38 373 (79.3) | − | − | − | − |
| NM | 7095 (14.6) | ||||
| LMM | 2500 (5.2) | ||||
| ALM | 429 (0.9) | ||||
| Sex, No. (%) | |||||
| Female | 27 270 (56.4) | 21 978 (57.3) | 3605 (51.1) | 1415 (56.6) | 272 (63.4) |
| Male | 21 091 (43.6) | 16 395 (42.7) | 3454 (48.9) | 1085 (43.4) | 157 (36.6) |
| Age at diagnosis, mean (SD), y | 56.39 (16.07) | 54.49 (15.44) | 61.07 (16.88) | 71.09 (12.37) | 63.70 (14.82) |
| 18-35 | 5118 (10.6) | 4507 (11.7) | 547 (8.1) | 22 (0.9) | 15 (3.5) |
| 36-55 | 17 974 (37.2) | 15 629 (40.7) | 1975 (28.0) | 261 (10.4) | 109 (25.4) |
| 56-75 | 18 899 (39.1) | 14 583 (38.0) | 2919 (41.4) | 1193 (47.7) | 204 (47.6) |
| >75 | 6370 (13.2) | 3554 (9.5) | 1591 (22.5) | 1024 (41.0) | 101 (23.5) |
| Breslow, median (IQR), mm | 0.86 (0.50-1.60) | 0.76 (0.50-1.20) | 2.80 (1.75-4.50) | 0.60 (0.38-1.00) | 2.02 (1.20-4.00) |
| 0.1-0.7 | 20 545 (42.5) | 18 716 (48.8) | 173 (2.5) | 1601 (64.0) | 55 (12.8) |
| 0.8-1.0 | 7987 (16.5) | 7269 (18.9) | 378 (5.4) | 309 (12.4) | 31 (7.2) |
| 1.1-2.0 | 10 576 (21.9) | 8263 (21.5) | 1815 (25.7) | 368 (14.7) | 130 (30.3) |
| 2.1-4.0 | 6148 (12.7) | 3161 (8.2) | 2717 (38.5) | 159 (6.4) | 111 (25.9) |
| >4.0 | 3105 (6.4) | 964 (2.5) | 1976 (28.0) | 63 (2.5) | 102 (23.8) |
| Localization, No. (%) | |||||
| Head and neck | 5983 (12.4) | 3186 (8.3) | 1137 (16.1) | 1660 (66.4) | 0 (0) |
| Trunk | 20 438 (42.3) | 17 527 (45.7) | 2651 (37.6) | 260 (10.4) | 0 (0) |
| Arms | 7035 (14.5) | 5442 (14.2) | 1231 (17.4) | 280 (11.2) | 82 (19.1) |
| Legs | 13 358 (27.6) | 10 969 (28.6) | 1805 (25.6) | 240 (9.6) | 334 (77.9) |
| Missing | 1547 (3.2) | 1249 (3.3) | 235 (3.3) | 60 (2.4) | 3 (0.7) |
| Ulceration, No. (%) | |||||
| No | 34 480 (71.3) | 29 233 (76.2) | 3243 (45.9) | 1176 (47.0) | 228 (53.2) |
| Yes | 6042 (12.5) | 3035 (7.9) | 2732 (38.7) | 128 (5.1) | 147 (34.3) |
| Missing | 7839 (16.2) | 6105 (15.9) | 1084 (15.4) | 1196 (47.8) | 54 (12.6) |
| AJCC stage at time of diagnosis, No. (%) | |||||
| I | 35 442 (73.3) | 31 586 (82.3) | 1535 (21.7) | 2160 (86.4) | 161 (37.5) |
| II | 10 618 (22.0) | 5347 (13.9) | 4727 (67.0) | 335 (13.4) | 209 (48.7) |
| III | 2301 (4.8) | 1140 (3.8) | 797 (11.3) | 5 (0.2) | 59 (13.8) |
| Deaths, No. (%) | 8619 (17.8) | 5230 (13.6) | 2665 (37.8) | 583 (23.3) | 141 (32.9) |
| Follow-up, median (IQR), mo | 73.8 (43.5-120.7) | 76.9 (45.8-123.9) | 62.6 (33.6-114.0) | 59.4 (34.4-97.2) | 56.6 (34.9-93.2) |
a
AJCC = American Joint Committee on Cancer; ALM = acral lentiginous melanoma; IQR = interquartile range; LMM = lentiginous malignant melanoma; NM = nodular melanoma; SSM = superficial spreading melanoma.